pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
BioNTech SE clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
BioNTech SE projects
5 ClinicalTrials.gov programs sponsored by BioNTech SE.
BioNTech SE has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BNT323-01
BioNTech SE
Endometrial cancer
1 trial -
BNT327-03
BioNTech SE
English First-line extensive-stage small-cell lung cancer (ES-SCLC)
1 trial -
BNT327-05
BioNTech SE
First line triple-negative breast cancer (TNBC)
1 trial -
BNT327-06
BioNTech SE
Non-small cell lung cancer
1 trial -
PEMBROLIZUMAB , BNT113
BioNTech SE
Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer
1 trial
Frequently asked questions
How many clinical projects does BioNTech SE have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.